Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.23
- Piotroski Score 6.00
- Grade Overweight
- Symbol (ATR)
- Company AptarGroup, Inc.
- Price $169.80
- Changes Percentage (0.63%)
- Change $1.07
- Day Low $167.74
- Day High $170.22
- Year High $178.03
AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
- Last Earnings 10/10/2024
- Ex-Dividend for 5/16 Dividend 10/24/2024
- Dividend Payable 11/14/2024
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $125.00
- High Stock Price Target $215.00
- Low Stock Price Target $45.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.66
- Trailing P/E Ratio 31.23
- Forward P/E Ratio 31.23
- P/E Growth 31.23
- Net Income $284.49 M
Income Statement
Quarterly
Annual
Latest News of ATR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Why the Chiefs' Patrick Mahomes-Xavier Worthy deep-ball game isn't clicking
Kansas City Chiefs quarterback Patrick Mahomes reflects on missed opportunities, particularly a deep pass in their game against the Buffalo Bills. Mahomes and rookie receiver Xavier Worthy aim to impr...
By The New York Times | 10 hours ago -
'Great to see him': Canadiens' Patrik Laine skates with teammates for first time since injury - Montreal | Globalnews.ca
Patrik Laine of the Montreal Canadiens returned to practice after a knee injury. He wore a non-contact jersey and is expected to make his debut in December. The team is excited to have him back and re...
By Global News | 1 day ago -
FDA issues CRL to Astellas' IZERVAY sNDA for geographic atrophy
The FDA issued a complete response letter for Astellas Pharma's IZERVAY sNDA due to statistical concerns about proposed labelling language, not safety or efficacy. Astellas aims to address the issues ...
By Yahoo! Finance | 1 day ago
